4.4 Article

Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe

期刊

JAMA PSYCHIATRY
卷 74, 期 5, 页码 465-475

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamapsychiatry.2017.0056

关键词

-

资金

  1. National Institute of Mental Health (NIMH) [R01 MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly and Company
  8. Ortho-McNeil Pharmaceutical, Inc
  9. GlaxoSmithKline
  10. Bristol-Myers Squibb
  11. Australian Government Department of Health and Ageing
  12. State of Sao Paulo Research Foundation Thematic Project [03/00204-3]
  13. Ministry of Health
  14. National Center for Public Health Protection
  15. Shenzhen Bureau of Health
  16. Shenzhen Bureau of Science, Technology, and Information
  17. Ministry of Social Protection
  18. Center for Excellence on Research in Mental Health (CES University)
  19. Medellin
  20. European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
  21. Fondo de Investigacion Sanitaria
  22. Instituto de Salud Carlos III, Spain [FIS 00/0028]
  23. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  24. Departament de Salut, Generalitat de Catalunya, Spain
  25. Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  26. Japanese and European Funds through United Nations Development Group Iraq Trust Fund
  27. Israel National Institute for Health Policy and Health Services Research
  28. National Insurance Institute of Israel
  29. Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]
  30. Lebanese Ministry of Public Health
  31. WHO (Lebanon)
  32. National Institute of Health/Fogarty International Center [R03 TW006481-01]
  33. Algorithm
  34. AstraZeneca
  35. Benta
  36. Bella Pharma
  37. Eli Lilly
  38. Lundbeck
  39. Novartis
  40. Servier
  41. Phenicia
  42. Union Pharmaceutique d'Orient SAL
  43. National Institute of Psychiatry Ramon de la Fuente grant [INPRFMDIES 4280]
  44. National Council on Science and Technology grant [CONACyT-G30544-H]
  45. New Zealand Ministry of Health
  46. Alcohol Advisory Council
  47. Health Research Council
  48. WHO (Geneva)
  49. WHO (Nigeria)
  50. Federal Ministry of Health, Abuja, Nigeria
  51. Health AMP
  52. Social Care Research AMP
  53. Development Division of the Public Health Agency
  54. National Institute of Health of the Ministry of Health of Peru
  55. European Economic Area Financial Mechanism and the Norwegian Financial Mechanism
  56. Polish Ministry of Health
  57. Champalimaud Foundation
  58. Gulbenkian Foundation
  59. Foundation for Science and Technology
  60. Ministry of Public Health
  61. Eli Lilly Romania SRL
  62. US NIMH [R01-MH059575, R01-MH61905]
  63. National Institute of Drug Abuse
  64. South African Department of Health
  65. University of Michigan
  66. Regional Health Authorities of Murcia
  67. Servicio Murciano de Salud
  68. Consejeria de Sanidad y Politica Social
  69. Fundacion para la Formacion e Investigacion Sanitarias of Murcia
  70. NIMH [U01-MH60220, R01 MH094425]
  71. Substance Abuse and Mental Health Services Administration
  72. Robert Wood Johnson Foundation [044708]
  73. John W. Alden Trust
  74. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP

向作者/读者索取更多资源

IMPORTANCE Generalized anxiety disorder (GAD) is poorly understood compared with other anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist on GAD outside a small number of affluent, industrialized nations. No population-based data exist on GAD as it is currently defined in DSM-5. OBJECTIVE To provide the first epidemiologic data on DSM-5 GAD and explore cross-national differences in its prevalence, course, correlates, and impact. DESIGN, SETTING, AND PARTICIPANTS Data come from the World Health Organization World Mental Health Survey Initiative. Cross-sectional general population surveys were carried out in 26 countries using a consistent research protocol and assessment instrument. A total of 147 261 adults from representative household samples were interviewed face-to-face in the community. The surveys were conducted between 2001 and 2012. Data analysis was performed from July 22, 2015, to December 12, 2016. MAIN OUTCOMES AND MEASURES The Composite International Diagnostic Interview was used to assess GAD along with comorbid disorders, role impairment, and help seeking. RESULTS Respondents were 147 261 adults aged 18 to 99 years. The surveys had a weighted mean response rate of 69.5%. Across surveys, DSM-5 GAD had a combined lifetime prevalence (SE) of 3.7%(0.1%), 12-month prevalence of 1.8%(0.1%), and 30-day prevalence of 0.8%(0). Prevalence estimates varied widely across countries, with lifetime prevalence highest in high-income countries (5.0% [0.1%]), lower in middle-income countries (2.8% [0.1%]), and lowest in low-income countries (1.6%[0.1%]). Generalized anxiety disorder typically begins in adulthood and persists over time, although onset is later and clinical course is more persistent in lower-income countries. Lifetime comorbidity is high (81.9% [0.7%]), particularly with mood (63.0%[0.9%]) and other anxiety (51.7%[0.9%]) disorders. Severe role impairment is common across life domains (50.6%[1.2%]), particularly in high-income countries. Treatment is sought by approximately half of affected individuals (49.2%[1.2%]), especially those with severe role impairment (59.4%[1.8%]) or comorbid disorders (55.8% [1.4%]) and those living in high-income countries (59.0%[1.3%]). CONCLUSIONS AND RELEVANCE The findings of this study show that DSM-5 GAD is more prevalent than DSM-IV GAD and is associated with substantial role impairment. The disorder is especially common and impairing in high-income countries despite a negative association between GAD and socioeconomic status within countries. These results underscore the public health significance of GAD across the globe while uncovering cross-national differences in prevalence, course, and impairment that require further investigation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据